Topic Editors

Center for Craniofacial Molecular Biology, Norris Comprehensive Cancer Center, Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA
Dr. Uttam K. Sinha
Tina and Rick Caruso Department of Otolaryngology Head and Neck Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA

Upper Aerodigestive Tract Cancer

Abstract submission deadline
closed (20 September 2023)
Manuscript submission deadline
closed (20 December 2023)
Viewed by
5422

Topic Information

Dear Colleagues,

Upper aerodigestive tract cancer (UATC) is aggressive malignancy derived from stratified epithelium of the upper aerodigestive tract, including oral cavity, larynx and oropharynx, and esophagus. Over one million new cases of UATC are diagnosed worldwide every year, with oral and esophageal cancers being the most common types. Human papillomavirus (HPV)-positive and -negative tumors are considered distinct diseases with distinguishing biological and clinical features. Effective targeted regimens are still unavailable for most UATC, which is highly aggressive. For example, 5-year survival rate of oral cancer patients is approximately 50%. Conventional cytotoxic chemotherapeutic options for oral cancer patients are limited and often ineffective. More importantly, the short-term effects (e.g., mucositis, odynophagia) and long-term toxicities (e.g., xerostomia, dysphagia, ototoxicity) from treatment substantially affect quality of life and rival the impact of the cancer itself. This Topic aims to highlight the latest advances in both basic and clinical studies on UATC, with the goal of promoting research of pathophysiology of UATC to advance the healthcare and life quality of its patients. Original research papers and review articles are welcomed.

Dr. De-Chen Lin
Dr. Uttam K. Sinha
Topic Editors

Keywords

  • head and neck cancer
  • esophageal cancer
  • human papillomavirus

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
5.2 7.4 2009 17.9 Days CHF 2900
Cells
cells
6.0 9.0 2012 16.6 Days CHF 2700
Current Oncology
curroncol
2.6 2.6 1994 18 Days CHF 2200
Journal of Clinical Medicine
jcm
3.9 5.4 2012 17.9 Days CHF 2600
Journal of Personalized Medicine
jpm
3.4 2.6 2011 17.8 Days CHF 2600

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
19 pages, 5978 KiB  
Article
Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma
by Sara Lucila Lorenzo-Guerra, Helena Codina-Martínez, Laura Suárez-Fernández, Virginia N. Cabal, Rocío García-Marín, Cristina Riobello, Blanca Vivanco, Verónica Blanco-Lorenzo, Paula Sánchez-Fernández, Fernando López, Jóse Luis Llorente and Mario A. Hermsen
Cells 2024, 13(1), 81; https://doi.org/10.3390/cells13010081 - 30 Dec 2023
Viewed by 1072
Abstract
Sinonasal teratocarcinosarcoma (TCS) is a rare tumor that displays a variable histology with admixtures of epithelial, mesenchymal, neuroendocrine and germ cell elements. Facing a very poor prognosis, patients with TCS are in need of new options for treatment. Recently identified recurrent mutations in [...] Read more.
Sinonasal teratocarcinosarcoma (TCS) is a rare tumor that displays a variable histology with admixtures of epithelial, mesenchymal, neuroendocrine and germ cell elements. Facing a very poor prognosis, patients with TCS are in need of new options for treatment. Recently identified recurrent mutations in SMARCA4 may serve as target for modern therapies with EZH1/2 and CDK4/6 inhibitors. Here, we present the first in vitro cell line TCS627, established from a previously untreated primary TCS originating in the ethmoid sinus with invasion into the brain. The cultured cells expressed immunohistochemical markers, indicating differentiation of epithelial, neuroepithelial, sarcomatous and teratomatous components. Whole-exome sequencing revealed 99 somatic mutations including SMARCA4, ARID2, TET2, CDKN2A, WNT7A, NOTCH3 and STAG2, all present both in the primary tumor and in the cell line. Focusing on mutated SMARCA4 as the therapeutic target, growth inhibition assays showed a strong response to the CDK4/6 inhibitor palbociclib, but much less to the EZH1/2 inhibitor valemetostat. In conclusion, cell line TCS627 carries both histologic and genetic features characteristic of TCS and is a valuable model for both basic research and preclinical testing of new therapeutic options for treatment of TCS patients. Full article
(This article belongs to the Topic Upper Aerodigestive Tract Cancer)
Show Figures

Figure 1

16 pages, 1636 KiB  
Review
Preventive and Therapeutic Effect of Metformin in Head and Neck Cancer: A Concise Review
by Cyril Bouland, Xavier Vanden Eynden, Martin Lalmand, Thibaut Buset, Antoine Yanni, Rokneddine Javadian, Alexandra Rodriguez, Isabelle Loeb, Jérôme R. Lechien, Fabrice Journe, Sven Saussez and Didier Dequanter
J. Clin. Med. 2023, 12(19), 6195; https://doi.org/10.3390/jcm12196195 - 25 Sep 2023
Viewed by 943
Abstract
Background: Head and neck cancer (HNC) is a complex affection. Nowadays, conventional treatments are associated with many side effects, reducing the patient’s quality of life. Recent studies suggest that metformin, a first-line treatment for diabetes, could decrease cancer incidence and improve cancer-related survival [...] Read more.
Background: Head and neck cancer (HNC) is a complex affection. Nowadays, conventional treatments are associated with many side effects, reducing the patient’s quality of life. Recent studies suggest that metformin, a first-line treatment for diabetes, could decrease cancer incidence and improve cancer-related survival rates. Methods: This systematic review summarizes important data from studies evaluating metformin’s contribution to preventing and treating HNC. Results: The results suggest a protective effect of metformin in HNC. However, no consensus has been found on its therapeutic effects. Metformin seems to confer an improved cancer-related survival rate in a diabetic population, but compared to a non-diabetic population, the review could not identify any advantages. Nevertheless, no studies presented a negative impact. Conclusion: In conclusion, the results of this systematic review suggest that HNC patients may benefit from metformin. Indeed, it would reduce the HNC incidence. However, more studies are required to evaluate the effect on cancer-related survival rates. Full article
(This article belongs to the Topic Upper Aerodigestive Tract Cancer)
Show Figures

Figure 1

12 pages, 539 KiB  
Article
Role of Lower Esophageal Squamous Cell Carcinoma Margin Location on Abdominal Lymph Node Metastasis Risk
by Xia Zhong, Xue-Hua Tu, Gu-Ha A-Lai, Ze-Guo Zhuo, Peng Yao, Ying Zhang, Zhi-Jie Xu and Yi-Dan Lin
J. Clin. Med. 2023, 12(7), 2657; https://doi.org/10.3390/jcm12072657 - 03 Apr 2023
Viewed by 2128
Abstract
Background: Different sites of esophageal cancer are accompanied by different regional lymph node metastasis (LNM) risks. We aimed to investigate the impact of a lower tumor margin on abdominal LNM risk. Methods: We enrolled patients who underwent esophagectomy for esophageal squamous carcinoma (ESCC) [...] Read more.
Background: Different sites of esophageal cancer are accompanied by different regional lymph node metastasis (LNM) risks. We aimed to investigate the impact of a lower tumor margin on abdominal LNM risk. Methods: We enrolled patients who underwent esophagectomy for esophageal squamous carcinoma (ESCC) from 2014 to 2017 in West China Hospital. Overall survival (OS) analysis was performed. We measured the distance between the lower tumor margin and esophagogastric junction (LED) with upper gastrointestinal contrast-enhanced X-ray (UGCXR). Multivariate logistic regression analysis and propensity score matching (PSM) were performed to explore the relationship between LED and the risk of abdominal LNM. Abdominal LNM risk in ESCC was stratified based on the location of the lower tumor margin. A model predicting abdominal LNM risk was constructed and presented with a nomogram. Results: The included patients had an abdominal LNM rate of 48.29%. In multivariate logistic regression analysis, LED was identified as a risk factor for abdominal LNM. Subgroup analysis of middle ESCC showed that patients with an LED less than 10 cm had a significantly higher rate of abdominal LNM than those with an LED greater than 10 cm. The abdominal LNM rate in middle ESCC patients with an LED less than 10 cm was 32.2%, while it was 35.1% in lower ESCC patients whose lower tumor margin did not invade the esophagogastric junction (EGJ), which was comparable after PSM. Conclusions: LED could help surgeons evaluate the risk of abdominal LNM preoperatively and better guide dissection of abdominal lymph nodes according to risk level. Full article
(This article belongs to the Topic Upper Aerodigestive Tract Cancer)
Show Figures

Figure 1

Back to TopTop